A retrospective, cohort study assessing Letermovir discontinuation at day 100 after allogeneic stem cell transplant is associated with increased CMV-related mortality
Latest Information Update: 19 Aug 2022
At a glance
- Drugs Letermovir (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
Most Recent Events
- 19 Aug 2022 New trial record
- 01 Aug 2022 Primary endpoint (csCMVi at day 180) has been met according to the results published in the Transplantation and Cellular Therapy
- 01 Aug 2022 Results published in the Transplantation and Cellular Therapy